Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 317

1.

Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.

Richardson MW, Grewal SS.

Pediatr Blood Cancer. 2008 Jan;50(1):186. No abstract available.

PMID:
17455313
2.

[Chronic myeloid leukemia and imatinib mesylate therapy].

Chrobák L.

Vnitr Lek. 2004 Jan;50(1):10-2. Czech. No abstract available.

PMID:
15015223
3.

[Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].

Bulum J, Labar B, Mikulić M, Bogdanić V, Sertić D, Nemet D, Krecak-Gverić V, Kovacević J, Serventi-Seiwerth R, Mrsić-Davidović S, Zadro R, Boban D.

Lijec Vjesn. 2003 Jul-Aug;125(7-8):176-9. Croatian.

PMID:
14692090
4.

CML: imatinib mesylate (Glivec) or something else?

Ghosh A.

Nepal Med Coll J. 2007 Dec;9(4):292. No abstract available.

PMID:
18298026
5.

Imatinib mesylate.

[No authors listed]

Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. No abstract available.

PMID:
11765724
6.

Imatinib and chronic-phase leukemias.

Boros LG, Lee WN, Cascante M.

N Engl J Med. 2002 Jul 4;347(1):67-8. No abstract available.

8.

Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.

Arancibia AM, Bendit I, Epelman S.

Pediatr Blood Cancer. 2008 May;50(5):1078. No abstract available.

PMID:
18085674
9.

Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.

Ueda K, Horiike S, Zen K, Misawa S, Taniwaki M.

Leuk Lymphoma. 2006 Sep;47(9):1967-9. No abstract available.

PMID:
17065015
10.

Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.

Koca E, Cetiner D, Goker H, Aksu S, Ozcebe OI, Haznedaroglu IC, Turgan C.

Clin Nephrol. 2005 Oct;64(4):324-6. No abstract available.

PMID:
16240908
11.

Update on the use of imatinib mesylate.

Sawyers CL.

Clin Adv Hematol Oncol. 2005 Oct;3(10):757-8. No abstract available.

PMID:
16258483
12.

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

Druker BJ.

Oncogene. 2002 Dec 9;21(56):8541-6. Review. No abstract available.

13.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Goldman JM, Melo JV.

N Engl J Med. 2001 Apr 5;344(14):1084-6. No abstract available.

PMID:
11287980
14.

Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.

O'Dwyer ME, La Rosée P, Nimmanapalli R, Bhalla KN, Druker BJ.

Semin Hematol. 2002 Apr;39(2 Suppl 1):18-21. Review.

PMID:
12012318
15.
16.

Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.

Ossard-Receveur A, Bernheim A, Clausse B, Danglot G, Fauvet D, Leon B, Lozach F, Bories D, Brouzes C, Bourhis JH, Turhan AG.

Cancer Genet Cytogenet. 2005 Dec;163(2):189-90. No abstract available.

PMID:
16337868
17.

3. Imatinib therapy in chronic myelogenous leukemia.

Jinnai I.

Intern Med. 2007;46(2):95-7. Epub 2007 Jan 15. Review. No abstract available.

18.

STI571: a magic bullet?

Verweij J, Judson I, van Oosterom A.

Eur J Cancer. 2001 Oct;37(15):1816-9. Review. No abstract available.

PMID:
11576833
19.

A hope for the future.

Silver RT.

Cancer Invest. 2003 Jun;21(3):486. No abstract available.

PMID:
12901295
20.

Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.

Bornhäuser M, Pursche S, Bonin M, Freiberg-Richter J, Jenke A, Illmer T, Ehninger G, Schleyer E.

J Clin Oncol. 2005 Jun 1;23(16):3855-6; author reply 3857-8. No abstract available.

PMID:
15923584

Supplemental Content

Support Center